دورية أكاديمية
A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
| العنوان: | A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab |
|---|---|
| المؤلفون: | Naoto Saito, Takeshi Hatanaka, Sachi Nakano, Yoichi Hazama, Sachiko Yoshida, Yoko Hachisu, Yoshiki Tanaka, Teruo Yoshinaga, Kenji Kashiwabara, Norio Kubo, Yasuo Hosouchi, Hiroki Tojima, Satoru Kakizaki, Toshio Uraoka |
| المصدر: | Clinical Case Reports, Vol 10, Iss 7, Pp n/a-n/a (2022) |
| بيانات النشر: | Wiley, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Medicine LCC:Medicine (General) |
| مصطلحات موضوعية: | anti‐programmed death ligand‐1, hepatic resection, immune checkpoint inhibitor, liver cancer, vascular endothelial growth factor, Medicine, Medicine (General), R5-920 |
| الوصف: | Abstract An 81‐year‐old man initially underwent right hepatic lobectomy for liver cancer and was pathologically diagnosed with combined hepatocellular and cholangiocarcinoma (CHC). At 13 months after resection, multiple lymph node metastases were observed. We started atezolizumab plus bevacizumab (Atez/Bev), achieving a 7.5‐month progression‐free survival. Atez/Bev might exhibit efficacy for CHC patients. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2050-0904 |
| العلاقة: | https://doaj.org/toc/2050-0904Test |
| DOI: | 10.1002/ccr3.6129 |
| الوصول الحر: | https://doaj.org/article/2cd1c635ef1d44faa870f54f525fdf8dTest |
| رقم الانضمام: | edsdoj.2cd1c635ef1d44faa870f54f525fdf8d |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20500904 |
|---|---|
| DOI: | 10.1002/ccr3.6129 |